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OBJECTIVE — We developed a novel population-level model for projecting future direct
spending on diabetes. The model can be used in the federal budget process to estimate the cost
implications of alternative policies.
RESEARCH DESIGN AND METHODS — We constructed a Markov model simulating
individuals’ movement across different BMI categories, the incidence of diabetes and screening,
and the natural history of diabetes and its complications over the next 25 years. Prevalence and
incidenceofobesityanddiabetesandthedirectspendingondiabetescareandcomplicationsare
projected. The study population is 24- to 85-year-old patients characterized by the Centers for
Disease Control and Prevention’s National Health and Nutrition Examination Survey and Na-
tional Health Interview Survey.
RESULTS — Between 2009 and 2034, the number of people with diagnosed and undiag-
nosed diabetes will increase from 23.7 million to 44.1 million. The obesity distribution in the
population without diabetes will remain stable over time with 65% of individuals of the
population being overweight or obese. During the same period, annual diabetes-related
spending is expected to increase from $113 billion to $336 billion (2007 dollars). For the
Medicare-eligible population, the diabetes population is expected to rise from 8.2 million in
2009 to 14.6 million in 2034; associated spending is estimated to rise from $45 billion to
$171 billion.
CONCLUSIONS — The diabetes population and the related costs are expected to at least
double in the next 25 years. Without signiﬁcant changes in public or private strategies, this
population and cost growth are expected to add a signiﬁcant strain to an overburdened health
care system.
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T
hehighcostofcaringforindividuals
with chronic diseases is one of the
most pressing issues in health care
in the U.S. today (1). The baby boom
generation is aging, and advanced age is
accompanied by costly chronic ill-
nesses. As a result, Medicare and other
health-related governmental programs
will face demographic and epidemio-
logical forces that will challenge their
ﬁnancial viability.
In light of the sheer magnitude of
costs associated with diabetes, policy-
makers and the public need to under-
standhowthesecostswillchangeoverthe
next decades and how new policies may
alter these trends in costs. Policymakers
already are keenly interested in develop-
ingandpursuingpoliciesthatcanprevent
the expected rise in disease burden and
head off expensive public commitments
to care for the chronically ill.
The forecasting effort presented in
this article speaks directly to this concern
by improving the rigor of the estimates of
health outcomes and health care spend-
ing associated with future trends in the
incidence, prevalence, and progression
toward complications. We constructed a
model of diabetes costs that accounts for
the trends in risk factors for diabetes, the
natural history of disease, and the effects
of treatments—factors currently not used
bygovernmentbudgetanalysts.Inclusion
of these factors in forecasting models can
improve estimates under current trends
and policies, and more importantly, fore-
cast the impact of alternative policy
scenarios.
Overall costs related to type 2 diabe-
teswillbeinﬂuencedbythedemographic
shifts in the population, population-level
trends in obesity, the development and
dissemination of new diabetes-related
treatments, and diagnostic tests. Recent
trends in obesity rates and major ad-
vancesintheunderstandingofthenatural
historyofdiabeteshavenotbeenformally
incorporated into prior forecasts of the
burden of diabetes (2–4). We set out to
integrate recent prediction models and
epidemiological data for obesity, diabetes
incidence, and diabetes complications to
forecast the future size of the diabetic
population and their related health care
costs.
RESEARCH DESIGN AND
METHODS— Estimates of future to-
talhealthcarecostsfordiabetesmusttake
into account two dynamic processes.
First, the diabetes population is con-
stantly changing over time. New people
are diagnosed and added to the popula-
tion;contemporaneously,otherindividu-
als with existing diabetes die and leave
this subpopulation. With the balance of
these two processes, the prevalence of di-
abetes in the total population changes on
an annual basis. The pace of change dif-
fers over time depending on factors such
as the rate of obesity and age of those at
risk. For instance, the aging of the large
baby boom generation will bring large
numbers of new people into age catego-
ries that are at higher risk of developing
the disease.
Second, costs associated with diabetes
tend to follow a natural progression over
time. Complications take time to develop
andinﬂictdamagetotheeyes,kidneys,and
circulatoryandnervoussystems.Therefore,
robust projection models must include es-
timates of the expected natural history of
thediseasebasedonalternativelevelsofdis-
ease management.
In developing our forecasting model,
we account for two types of cohorts—a
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prevalent cohort is the population of in-
dividualswithdiabetesin2008.Itreﬂects
the distribution of different ages and dif-
ferentyearswithdiabetesofthesubpopu-
lation in 2008. The second type of cohort
is the incident cohort. This group repre-
sents the new people with diabetes enter-
ing the diagnosed population each year
afterthebaseyearof2008.Thenumberof
people with diabetes in any year is the
sum of the population in the previous
year (in 2008, it is the prevalent cohort)
and the incident cohort, minus deaths
fromallcausesinthepreviousyear’spop-
ulation with diabetes.
To account for the costs of both co-
horts,wetrackedcostsusingtwotimelines:
1) the chronological timeline during which
wewillreportourtotalcostestimatesand2)
the age timeline for various heterogeneous
subgroups within the prevalent and inci-
dent cohorts. For example, different pa-
tients may start with diabetes at different
ages in the same calendar year. Other pa-
tients may start at the same age but in dif-
ferent calendar years.
We developed explicit models to ad-
dressthisdynamicnatureofcostaccumu-
lation. Figure 1 presents the conceptual
accounting of costs over time. This in-
volves accounting for all health care costs
incurred for the prevalent groups of peo-
ple with diabetes, after the annual inci-
dent cohort for that year joins the
prevalent cohort (illustrated by a dotted
boxinFig.1).Empirically,weaccountfor
costs horizontally (as represented by ar-
rows in Fig. 1). That is, we take the prev-
alent cohort of patients in 2008 and lay
out their lifetime cost proﬁles through-
out the calendar time starting from
2008. Similarly, we take the incident
cohort of patients in 2009 and lay out
their lifetime cost proﬁles throughout
the calendar time starting from 2009.
We repeat this pattern for future inci-
dent cohorts of patients. We also ac-
count for heterogeneity in terms of
patient characteristics for all cohorts.
There are three components that are
central to estimating this accumulation of
costs:1)deﬁningtheprevalentcohortand
its heterogeneity, 2) the diabetes inci-
dence model, and 3) the lifetime simula-
tion model for diabetes progression.
Deﬁning the prevalent cohort and its
heterogeneity
We assume that the prevalent cohort of
adult patients living with diabetes has the
demographic and clinical characteris-
tics of adult individuals reporting that
they have diabetes in the National
Health and Nutrition Examination Sur-
vey (NHANES) (2005–2006).
To create the prevalent cohort, we
used self-reported disease to identify
individuals with diabetes. We then
estimated the U.S. population with di-
agnosed diabetes, undiagnosed diabetes,
and no diabetes, categorized by sex, race/
ethnicity, and age from 24 to 85 years.
Because few clinical trial results include
populations under 24 or over 85 years,
this age range allows the model to esti-
mate the effects of clinical trial results on
the entire study population. Lifetime
diabetes-related costs for the prevalent
cohort are estimated using the lifetime
simulation model for diabetes progres-
sion described below.
The diabetes incidence model
Themainpurposeoftheincidencemodelis
to account for new cases of undiagnosed
and diagnosed diabetes in the population
over time. Once new subjects are diag-
nosed, their lifetime costs are calculated us-
ing the cost estimates arising out of the
lifetime model of diabetes progression.
Appendix Fig. S1A (available in
an online appendix at http://care.
diabetesjournals.org/cgi/content/full/dc09-
0459/DC1) displays the basic structure of
the Markov model that traces the transi-
tion of the U.S. population across BMI
categories over the age of the subjects.
These transition probabilities determine
the distribution of BMI categories at any
point in time, which in turn affects the
transition to diabetes. Online appendix
Fig.S1Bdisplaysthebasicstructureofthe
Markov model that tracks the movement
of the population between four main
states: 1) no diabetes, 2) undiagnosed di-
abetes, 3) diagnosed diabetes, and 4)
death. It also displays the key transition
probabilities driving the results of the
model.
A fraction of the population without
diabetes, conditional on their survival
(death rate is denoted by d) to the next
period, may progress to have diabetes.
Annual progression rates are denoted by
the parameter r. These people transition
to become diagnosed or to remain undi-
agnosed with diabetes depending on
whether they are screened. Annual
screeningratesaredenotedbytheparam-
eter s. Similarly, depending on whether
they are screened, those with currently
undiagnosed diabetes transition to be-
come diagnosed or remain undiagnosed.
(Here we assume that the screening test is
100% sensitive and speciﬁc). As men-
tioned above, the group with diagnosed
diabetes then is removed from this model
andfedintothelifetimesimulationmodel
described below. The others continue.
Initial distribution of BMI categories
are obtained from NHANES data (2005–
2006). Yearly transitions across BMI cat-
egories are estimated using the 2004–
2005 longitudinal data on the Panel 9
cohort from the Medical Expenditure
Panel Survey. Estimates of d are obtained
from published U.S. Life Tables (2004).
EstimatesofsareobtainedfromNHANES
data (2005–2006). Finally, estimates of r
are obtained by ﬁtting the Markov model
to published incidence rates from the
Centers for Disease Control and Preven-
tion (using the National Health Interview
Survey) (5). All parameters are allowed to
Figure 1—Conceptual model of costs of diabetes with prevalent and future cohorts over time.
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smoothed over ages 24–85 years. Esti-
mates of r are separately smoothed for
age-groups 45, 45–64, and 64 years
due to substantial heterogeneity across
these age ranges.
Age-speciﬁc annual hazard of pro-
gression to diabetes for people without
diabetes for different sexes and BMI cate-
gories are calculated based on observed
incidence of people with diagnosed dia-
betes and current screening rates. The
progression hazards increase monotoni-
cally with age in all categories and are
highestfortheobesecategoryfollowedby
overweight and normal at all ages.
Lifetime simulation model of
diabetes complications
Withina1-yearcycle,patientsmovefromone
disease state to another or stay in the current
disease state until death or age 95 years.
Online appendix Fig. S2 displays the
design of the model of diabetes complica-
tions.Thisﬁgurepresentsthestructureof
the decision analytic model. Hypothetical
patients move through the model from
left to right for each cycle length (1 year).
Based on initial patient clinical character-
istics, patients are subject to the risk of
various complications related to diabetes
as well as mortality. Patients who survive
a given year repeat the cycle until death.
Data on demographic characteristics
(sexandrace/ethnicity)aswellasrelevant
clinical characteristics (blood pressure
levels, cholesterol levels, GHb levels, and
duration of diabetes) are obtained from
NHANES and used as data inputs for the
simulation models. For each clinical risk
factor, we use age-, sex-, and race/
ethnicity-speciﬁc distributions of these
factors within the models.
The diabetes complication models in
this analysis are derived from U.K. Pro-
spective Diabetes Study (UKPDS) results
(6). Prediction models for all major
diabetes-related complications have been
developed by the UKPDS study group
(7,8). These models have been internally
and externally validated with cardiovas-
cular trial data (9). The UKPDS model
does not include glucose control as a pre-
dictor,makingitunsuitableforevaluating
the impact of improved diabetes care on
end-stage renal disease. Instead, we mod-
eled the development of microalbumin-
uria and proteinuria, which are linked to
the intensity of glucose control (10). We
usedpredictionmodelsfortheseinterme-
diate complications using optimization
procedures to ﬁt observations from the
UKPDS control arm to a functional form
used in the original National Institutes of
Health model (11). For the transition be-
tween proteinuria to end-stage renal dis-
ease, we used probabilities from an
observational study (12).
For background mortality rates, we
used race/ethnicity- and sex-speciﬁc
background mortality rates reported in
U.S.lifetablestatisticsfrom1999(13).To
calculate background mortality rates for
individuals with diabetes, we subtracted
cardiovascularmortalityratesforthegen-
eral population from the overall mortality
rates found in life tables. We multiplied
these rates by 2.75 as previously done to
reﬂect higher background mortality rates
for patients with diabetes (11). When pa-
tients developed speciﬁc complications,
such as coronary heart disease, stroke,
end-stage renal disease, and amputation,
weassumedthatpatientshadhighermor-
tality rates attributable to these complica-
tions (14,15).
Within the model, we accounted for
the effect of individual medications. The
beneﬁts of ACE inhibitors were based on
the ﬁndings from the Heart Outcomes
Prevention Evaluation (HOPE) Study
(16). Aspirin was assumed to reduce the
probability of coronary heart disease but
to increase the probability of gastrointes-
tinal bleed (17). We assumed that the
joint effect of aspirin and an ACE inhibi-
toroncardiovasculareffectswasmultipli-
cative.Wedidnotassumethatsimplythe
processesofcaresuchasfootexamination
or routine laboratory tests independently
produced clinical beneﬁts (18).
Health service utilization and cost
inputs
We assumed that the use of medications
reﬂects the current distribution of use of
insulin, oral agents, insulin plus oral
agents, and diet therapy as observed in
nationalstudiesofdiabetescare(19).Dis-
tribution of use of different oral glucose-
lowering agents was assumed to be the
observed distribution in national studies
(20). Use of ACE inhibitors and aspirin
therapy was based on recent national re-
ports of diabetes care (21). Frequency of
ofﬁce visits and laboratory tests was as-
sumed to be that observed in a recent na-
tional study (22).
Weestimateddrugcostsbasedonthe
average type and frequency of drug pre-
scriptions, dosage of medications, and
wholesale drug prices. Annual costs of
microvascular and cardiovascular com-
plications were obtained from recent
studiesintheliterature(pleaseseetheon-
line appendix Table for details).
For this analysis, we used the compli-
cation model to predict the average an-
nual costs of living with diabetes by
different ages, sexes, racial groups, and
major durations of diabetes. A total of
10,000 Monte-Carlo iterations (each iter-
ation representing a patient life) were
used to generate average estimates. All
costs are expressed in 2007 USD. In esti-
mating costs for future years, we applied
the cost growth assumptions used by the
Congressional Budget Ofﬁce.
RESULTS— The results of our model
regarding overall population changes in
obesity, future population size, and
healthcarespendinghavebeenbrieﬂyde-
scribed in a related publication (23). We
expandonthoseresultsanddescribefore-
casts for the Medicare population.
Changes in obesity
Becauseourmodelpredictstheprogression
from non-diabetes to diabetes, we estimate
changesinpercentageofobese,overweight,
and normal-weight individuals in the pop-
ulationlivingwithoutdiabetes.Overallobe-
sity distribution in the non-diabetes
population remains fairly stable over time,
with 65% of the population being over-
weight or obese. The percentage catego-
rized as overweight in the non-diabetes
population is expected to remain steady at
35% over the time period. The percent cat-
egorized as obese is expected to drop
slightly from 30% in 2009 to 27% in 2033.
This same leveling of the obesity trend is
found in projections produced by the Cen-
ters for Disease Control and Prevention for
the U.S. population (24).
Future population size for the U.S.
We found that in 2009, there will be 19.5
million diagnosed and 4.25 million undi-
agnosed diabetes cases in the population
ages24–85years.Overthenext12years,
theoverallpopulationwithdiabetesisex-
pected to rise (Fig. 2). Among this popu-
lation, the distribution of diagnosed and
undiagnosed individuals will be shaped
by the rate of arrival of new cases and
continued screening for diabetes by the
medical system. The combined effect is
that the cohort of established diagnosed
diabetes will grow, while the cohort of
undiagnosed diabetes steadily declines
and stabilizes at around 3.7 million by
2020. After 2020, the size of the cohort of
people with undiagnosed diabetes is esti-
Huang and Associates
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hort size follows the same pattern.
The growth of the Medicare popula-
tion follows many of the same trends for
the overall population with diabetes. For
2009, the model projects 6.5 million
Medicare-eligible beneﬁciaries with prev-
alent diagnosed diabetes. During 2009,
0.9 million will be newly diagnosed with
diabetes, while another 0.9 million will
remain undiagnosed. By 2034, the num-
ber of individuals with diagnosed diabe-
tes eligible for Medicare will rise to 14.1
million, while the size of the annual co-
hort with undiagnosed diabetes will de-
crease to 440,000.
Spending associated with the direct
care of diabetes and its
complications
For this analysis, we projected direct
spending on diabetes and its complica-
tions for the next 25 years (Fig. 3). The
sum of spending for the cohort that cur-
rently has diabetes (the prevalent cohort)
and the spending for the populations ex-
pectedtobediagnosedduringthenext25
years (the incident cohorts) determines
the total costs of diabetes in future years.
In the next 25 years, annual spending is
expected to increase steeply to approx-
imately $336 billion (in constant 2007
USD), mainly because of the increasing
size of the incident cohorts. The annual
costsshouldstabilizefromthatpointon
as the size of the incident cohort pla-
teaus. Similarly, Medicare spending on
diabetes care is estimated to rise from
$45 billion in 2009 to $171 billion in
2034. Based on these estimates, Medi-
care spending alone will represent just
over50%ofdirectspendingondiabetes
in 2034.
CONCLUSIONS— We project that
over the next 25 years, the number of
Americans with diagnosed and undiag-
nosed diabetes will increase from 23.7
million to 44.1 million. During the same
time period, annual spending related to
diabetes is expected to increase from
$113billionto$336billion(inconstant
2007 USD). These changes are driven
more by the size of incoming age co-
horts than by changes in obesity and
overweight rates. For Medicare, the
project growth in diabetes care spend-
ing exceeds current projections of
spending by Medicare and for the
growth domestic product.
Our analysis is distinct from prior ef-
forts to forecast the future size of the dia-
betes population. Prior studies have
accounted for the changing size and age
compositionoftheoverallpopulationand
assumed ﬁxed age-speciﬁc and sex-
speciﬁc prevalence rates (2,3).
Morerecently,Boyleetal.(4)demon-
strated the important impact of changes
in the ethnic composition of the popula-
tion on the projected burden of diabetes.
Our study is distinct in its accounting for
the evolving nature of the distribution of
body weight categories in the population.
Our analysis is also unique in its account-
ing for the natural history of diabetes
complications. Both innovations enhance
our ability to forecast the future costs at-
tributable to diabetes.
We built this model to improve the
budgetary and health outcome informa-
tion available to federal policymakers.
The model provides a rigorous assess-
mentofthefutureburdenofdiabetesthat
accountsforthenaturalhistoryofthedis-
ease and recent advances in treatment.
More importantly, the model can also be
used to provide estimates of the impact of
alternative policy scenarios. Current
practices by federal scorekeeping agen-
cies do not approach cost estimating in
this manner, nor do they generally pro-
vide estimates beyond 10 years. This dia-
betes model is also meant to serve as an
Figure 2—Projected distribution of newly diagnosed, undiagnosed, and established cases of
diabetes, 2009–2034.
Figure 3—Projected direct spending on diabetes and its complications for different cohorts,
2008–2033. Reprinted with permission from Huang et al. (23).
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that can be used by policymakers when
consideringpoliciesforotherchronicdis-
eases. Such models are appropriate when
abundant epidemiological data are avail-
able to forecast the natural history of dis-
ease incidence and progression, as is the
case with type 2 diabetes.
The study has several limitations. First,
attemptstoforecastfuturecostsandutiliza-
tions are conditional on current rates of uti-
lization. For example, we have used the
mostcurrentestimatesofscreeningratesfor
diabetes from NHANES. However, rates
change over time, and future changes may
inﬂuence our results. Our model also does
not account for individuals under 24 years
of age who enter the population. This limi-
tationmaybeparticularlyrelevantforaccu-
rately incorporating diabetes prevalence
andincidenceintheimmigrantpopulation,
whomayexperienceheterogeneousratesof
developing the disease (25). Lastly, during
our analysis of transitions across BMI cate-
gories, we grouped all individuals who had
BMIs 30 kg/m
2. We did this because of a
lack of available Medical Expenditure Panel
Surveydatatomodeltransitionsacrossﬁner
BMI categories. Many of these limitations
may lead to more conservative estimates of
the future size of the diabetes populations
and their costs.
Despite these limitations, our study
strongly suggests that diabetes will grow in
thecomingdecades,bothinpopulationsize
and costs, and will have signiﬁcant impacts
on the lives of Americans and the ﬁnancial
viability of programs like Medicare. Fore-
casting models like this can help policy-
makersanticipatefutureburdensofchronic
diseases and design targeted policies that
ﬁght these diseases in the most effective
ways possible, both in terms of clinical ef-
fectiveness and cost-effectiveness.
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